Fig. 1: Serum IL-22 levels on PICU admission were decreased in septic patients with liver injury and the fall-down of serum IL-22 level was associated with LPS-induced acute liver injury.
From: IL-22 ameliorates LPS-induced acute liver injury by autophagy activation through ATF4-ATG7 signaling
IL-22 concentrations were measured by ELISA in serum samples collected from 41 patients with sepsis (sepsis). a Serum IL-22 concentrations in survivors and non-survivors with sepsis, b serum IL-22 concentrations in septic patients with (sepsis-AKI) or without acute kidney injury (sepsis), c serum IL-22 concentrations in septic patients with (sepsis-RF) or without respiratory failure (sepsis), d serum IL-22 concentrations in septic patients with (sepsis-GI dysfunction) or without gastrointestinal (GI) dysfunction (sepsis), e serum IL-22 concentrations in septic patients with (sepsis-ALI) or without acute liver injury (sepsis), f ROC curve for IL-22 as a predictor for sepsis-associated liver injury (SALI), g serum IL-22 concentrations in LPS-treated mice at indicated time (1, 2, 4, 8, 24, 48 h) after LPS treatment (5 mg/kg body weight, i.p, once) (n = 5). h Hematoxylin and Eeosin staining (H&E staining) of liver sections from mice treated with LPS for different time. * indicates the significant difference compared with control group (0 h), p < 0.05.
